Morning vs. afternoon infusions: could timing boost cancer treatment?
NCT ID NCT07630168
First seen Jun 07, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This study looks at whether getting immunotherapy in the morning or afternoon changes how well it works for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to receive their infusions before noon or after 3 PM. Researchers will track survival and tumor response for up to 2 years to see if timing makes a difference.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina at Chapel Hill, Department of Radiation Oncology
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1/PD-L1 inhibitor (immunotherapy)
What this could lead to
If timing matters, this could lead to simple scheduling changes that improve how well immunotherapy works for some cancers.
What could go wrong
This is a phase 2 trial, so results are still uncertain. The effect of timing may be small or nonexistent, and findings may not apply to all patients or cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.